Your browser doesn't support javascript.
loading
Pleiotropic Effects With Equivalent Low-density Lipoprotein Cholesterol Reduction: Comparative StudyBetween Simvastatin and Simvastatin/Ezetimibe Coadministration
Araujo, Daniel B; Bertolami, Marcelo Chiara; Ferreira, Waldinai; Abdalla, Dulcineia S; Faludi, Andre A; Nakamura, Yara; Bricharello, Liliana P.
Afiliação
  • Araujo, Daniel B; Instituto Dante Pazzanese de Cardiologia. BR
  • Bertolami, Marcelo Chiara; Instituto Dante Pazzanese de Cardiologia. BR
  • Ferreira, Waldinai; Instituto Dante Pazzanese de Cardiologia. BR
  • Abdalla, Dulcineia S; University of São Paulo. BR
  • Faludi, Andre A; Instituto Dante Pazzanese de Cardiologia. BR
  • Nakamura, Yara; University of São Paulo. BR
  • Bricharello, Liliana P; University of São Paulo. BR
J Cardiovasc Pharmacol ; 55: 1-5, 2010.
Article em En | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1063651
Biblioteca responsável: BR79.1
Localização: BR79.1
ABSTRACT

Background:

Coadministration of any statin with ezetimibe is as effective as using high doses of the same statin in the reduction of low-density lipoprotein cholesterol (LDL-c). There may be othereffects called pleiotropics.

Objective:

To compare the effectiveness of 2 different treatments that obtain equivalent LDL-c reductions (80 mg of simvastatin, oncea day and coadministration of 10 mg of simvastatin and 10 mg of ezetimibe, once a day) over endothelial function and inflammation.

Methods:

Twenty-three randomized patients with hypercholesterolemia in a 2 3 2 crossover protocol were studied. Endothelial function was analyzed by ultrasound assessment of endothelialdependent flow-mediated vasodilation of the brachial artery, andinflammation was estimated by high-sensitivity C-reactive protein(hs-CRP).

Results:

LDL-c reduction was similar between the 2 treatments withsimvastatin/ezetimibe and with simvastatin (P , 0.001); no differencebetween treatments was found (P = 0.968). Both treatments improved significantly the endothelial function [3.61% with simvastatin/ ezetimibe (P = 0.003) and 5.08% with simvastatin (P , 0.001)]; no difference was found between the 2 treatments (P = 0.291). hs-CRP had a 23% reduction with simvastatin/ezetimibe (P = 0.004) and a 30% reduction with simvastatin alone (P = 0.01), with no significant difference between the 2 treatments (P = 0.380).

Conclusion:

The 2 forms of treatment presented similar pleiotropiceffects improvement in endothelial function and decrease in hs-CRP levels.
Assuntos
Buscar no Google
Adicionar na Minha BVS
Imprimir
XML
Coleções: 06-national / BR Base de dados: SES-SP / SESSP-IDPCPROD Assunto principal: Proteína C-Reativa / Hipercolesterolemia Tipo de estudo: Clinical_trials / Guideline Idioma: En Revista: J Cardiovasc Pharmacol Ano de publicação: 2010 Tipo de documento: Article
Buscar no Google
Adicionar na Minha BVS
Imprimir
XML
Coleções: 06-national / BR Base de dados: SES-SP / SESSP-IDPCPROD Assunto principal: Proteína C-Reativa / Hipercolesterolemia Tipo de estudo: Clinical_trials / Guideline Idioma: En Revista: J Cardiovasc Pharmacol Ano de publicação: 2010 Tipo de documento: Article